Certain Antipsychotic Drugs Increase Death Risk

.

Certain Antipsychotic Drugs Increase Death Risk

A US research being published in the British Medical Journal (BMJ), has revealed that the people taking specific antipsychotic drugs for their dementia condition are at a greater risk of dying than those, who do not take such medicines.

A group of researchers from Harvard Medical School reached at the above given conclusion after assessing 75,445 nursing-home residents across 45 states from 2001 to 2005. However, the risk of death assessment period was six months.

The study, which was partially funded by U. S. National Institute of Mental Health, has revealed that not every antipsychotic drug increases the death risk. There are certain drugs, which increases the risk and those being Aripiprazole, Haloperidol, Olanzapine, Quetiapine, Risperidone and Ziprasidone.

However, they need to conduct further research in order to measure the death risk in all these drugs among others. It is not the first time when warning in regard to antipsychotic medication has came into limelight.

In 2005, the U. S. Food and Drug Administration (FDA) announced that antipsychotic drugs, which are also known with a name of second-generation antipsychotics, are linked with increased risk of death in older people.

The FDA realized that elderly people suffering from dementia are not aware of the risk of the drugs. Henceforth, in 2008 they expanded the warning and affirmed that even neuroleptics are not good for the health and people should avoid taking it.

Dr. Anne Corbett, research manager at Alzheimer's Society, agreed with the study researchers that all antipsychotic drugs are not harmful for health. "For a minority of people with dementia antipsychotics should be used, but then only for up to 12 weeks, and under the correct circumstances. For the majority, they do far more harm than good”, she further affirmed.


Latest News

Rise in Russian Arms Sales In spite of a Drop Globally
PetSmart Sells itself with an $8.3Billion Deal
Falling Oil Prices Result in a Drop in Stocks
Shares of Amaya Fall Due to Probe Conducted by Securities Regulators
Americans Consumers Display Confidence In the Market with Gain in Sales
It’s Time to Hurry Up to Enrol in the First Phase of Affordable Care Act Health
After Merger with Alliance Boots,	Walgreen CEO will Retire
Falling Fuel Prices Lift Airline Profits But No Respite in Fares Expected
Citigroup to Pay Likely $2.7B as Legal Charge
Michael Jeffries Retires as the CEO of Abercrombie & Fitch
Deutsche Bank in Trouble Again in the U.S. for Alleged Tax Scheme
Popular Demand Brings French Toast Crunch Back on the Shelves